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The  Decade  of Vaccines  Collaboration  and  development  of  the  Global  Vaccine  Action  Plan  provides  a cata-
lyst and  unique  opportunity  for regulators  worldwide  to  develop  and  propose  a  global  regulatory  science
agenda  for  vaccines.  Regulatory  oversight  is critical  to allow  access  to  vaccines  that  are  safe,  effective,  and
of  assured  quality.  Methods  used  by regulators  need  to constantly  evolve  so  that  scientiﬁc  and  technologi-
cal  advances  are applied  to  address  challenges  such  as new  products  and  technologies,  and  also  to  provide
an increased  understanding  of  beneﬁts  and  risks  of  existing  products.  Regulatory  science  builds  on high-
quality basic  research,  and  encompasses  at least  two broad  categories.  First,  there  is  laboratory-based
regulatory  science.  Illustrative  examples  include  development  of  correlates  of  immunity;  or correlates  of
safety;  or  of  improved  product  characterization  and  potency  assays.  Included  in such science  would  be
tools to standardize  assays  used  for regulatory  purposes.  Second,  there  is  science  to develop regulatory
processes.  Illustrative  examples  include  adaptive  clinical  trial  designs;  or tools  to analyze  the  beneﬁt-
risk  decision-making  process  of  regulators;  or novel  pharmacovigilance  methodologies.  Included  in  such
science  would  be initiatives  to  standardize  regulatory  processes  (e.g.,  deﬁnitions  of  terms  for  adverse
events  [AEs]  following  immunization).  The  aim  of  a global  regulatory  science  agenda  is  to  transform
current  national  efforts,  mainly  by well-resourced  regulatory  agencies,  into  a coordinated  action  plan  to
support global  immunization  goals.  This  article  provides  examples  of  how  regulatory  science  has,  in  the
past,  contributed  to improved  access  to  vaccines,  and  identiﬁes  gaps  that  could  be  addressed  through
a global  regulatory  science  agenda.  The  article also  identiﬁes  challenges  to  implementing  a  regulatory
science  agenda  and  proposes  strategies  and  actions  to  ﬁll  these  gaps.  A  global  regulatory  science  agenda
will enable  regulators,  academics,  and  other  stakeholders  to converge  around  transformative  actions  for
innovation  in the  regulatory  process  to support  global  immunization  goals.
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. Introduction
Regulatory science is the foundation of regulatory decision-
aking and is used to assess the quality, safety, and efﬁcacy of
uman and veterinary medicines throughout their life-span. The
omains covered by regulatory science are considered to include
oth basic and applied biomedical sciences (such as microbiology,
enetics, pharmacology, and biostatistics), clinical trial method-
logy and epidemiology, and social sciences (such as decision
ciences, risk assessment, and communication). Regulatory science
ims to contribute to the development of new tools, standards, and
pproaches to assess the safety, efﬁcacy, quality, and performance
f regulated products.
. How has regulatory science contributed to improved
ccess to vaccines?
The impact of regulatory science on improved vaccine access
an be illustrated through some recent examples.
.1. New tests for evaluation of the live-attenuated oral
oliovirus vaccine (OPV): Mutant analysis by PCR and restriction
passage and testing in non-human primates. Expensive, techni-
cally demanding tests in old-world monkeys [1] were the main
safety tests initially used to assure against increased virulence of
the vaccine on growth for production purposes. Two outcomes of
regulatory science research have revolutionized testing for rever-
tants: (1) a molecular-based assay that used knowledge gained
from studies of mutations associated with attenuation in vaccine
strains; and (2) a transgenic mouse model that expresses the human
poliovirus receptor, allowing viral replication and pathogenesis,
similar to non-human primates and humans.
In the 1980s, major efforts were made to understand the molec-
ular basis of attenuation, and thus neurovirulence, in poliovirus
vaccines. The molecular procedure termed MAPREC was developed
to measure the proportion of revertants in vaccine bulks [2] and val-
idated through an international collaborative study, to become an
ofﬁcial method [3] which provides a more precise assessment of
vaccine batch consistency than the monkey test, and is more easily
performed.
At the same time that MAPREC was  being developed, the cellular
receptor for poliovirus was  identiﬁed [4].  The poliovirus receptor
cDNA was  used to prepare transgenic mice which, unlike other
mice, were sensitive to poliovirus infection and developed clinicalndonuclease cleavage (MAPREC) and transgenic mouse tests
The OPVs that have brought the Global Polio Eradication Ini-
iative close to success were developed by Dr. Albert Sabin bysigns of infection analogous to monkeys [5].  This alternative ani-
mal  model to the monkey was validated using vaccines of varying
degrees of virulence comparing results to those found in monkeys
[6]. A standard operating procedure was  developed, and the mouse
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est was accepted as a safety test for vaccines and incorporated into
fﬁcial WHO  Recommendations [3].  Introduction of the molecu-
ar and transgenic mouse-based methods resulted in more reliable
ontrol of poliovirus vaccine consistency, improving vaccine qual-
ty and availability.
.2. Development and use of alternative potency evaluations for
elease of pandemic H1N1 vaccine
In preparation for an impending inﬂuenza pandemic, inves-
igators from the National Institutes for Food and Drug Control
NIFDC) in China and the Centre for Vaccine Evaluation, Biologics
nd Genetic Therapies Directorate (BGTD) of Health Canada in 2006
egan jointly developing and validating new assays for vaccine
uality control and lot release [7–9]. One of the aims of this collab-
ration was to validate assays for vaccine release in the event that
nternational reference standards were not available for lot release
sing existing ofﬁcial methods. NIFDC led a collaborative project
imed at validating a novel quality-control assay involving deg-
ycosylation and electrophoretic analysis of hemagglutinins (HA)
rom multiple manufacturing sites [7].  This alternative method for
accine potency enabled the Chinese health authority to conﬁ-
ently approve the monovalent pandemic H1N1 vaccine one month
arlier than would have been possible using the conventional
otency assay, which requires development of antibody reagents,
nd helped to minimize the effects of the 2009 pandemic inﬂuenza
utbreak in China. Follow-up studies conﬁrmed that these vaccines
ad good safety and efﬁcacy proﬁles [10].
.3. Deﬁning international consensus values for serological
orrelates of immunity for pneumococcal vaccines
The ﬁrst vaccine of its kind normally undergoes full clinical
rotection studies for licensure, as was the case for the 7-valent
neumococcal conjugate vaccine ﬁrst licensed in 2000. How-
ver, with robust biological assays to support their use, correlates
nd/or surrogate markers of immunity were used to licence several
econd-generation vaccines, thus accelerating vaccine approval
nd availability. WHO  Recommendations for the production and
ontrol of pneumococcal conjugate vaccine [11] were developed
n the basis that due to practical and ethical considerations, it
ould be difﬁcult to perform protective efﬁcacy studies on new
neumococcal conjugate vaccines and that their licensure should
e based on immunogenicity studies against a licensed com-
arator vaccine. These Recommendations discussed the design
f appropriate immunogenicity studies: (1) It was  considered
ssential that immunogenicity studies with a new pneumococ-
al conjugate vaccine should provide a link to the efﬁcacy against
nvasive disease that had been demonstrated for the 7-valent
accine. (2) The immune responses to common serotypes in the
ew and the licensed comparator vaccine should be compared
n randomized non-inferiority clinical studies. (3) The criteria for
omparison should be based on serotype-speciﬁc IgG antibody con-
entrations measured by ELISA. (4) Measurement of functional
ntibody responses for a subset of vaccinated subjects using an
psonophagocytic assay (OPA) was an important additional crite-
ion in comparing immune responses between vaccines.
Critical to this approach to licensing new pneumococcal con-
ugate vaccines was the need to standardize the measurement
ssays as well as to reach an international consensus regarding the
riteria indicative of protection [12]. It is well known that biolog-
cal assays have inherent variability and that those are ampliﬁed
ith slightly different protocols or reagents. Therefore, manu-
acturers, academia, and regulatory agencies sought to develop
tandardized assays and acceptable cut-off points used to infer pro-
ection [12]. WHO  coordinated these activities, which resulted inS (2013) B163– B175 B165
the establishment of a WHO  reference ELISA to measure IgG anti-
body speciﬁc for individual pneumococcal capsular polysaccharide,
a quality-control sera panel for use in calibrating the ELISA, and an
International Standard pneumococcal serum. Also, two WHO  refer-
ence laboratories were established to facilitate the standardization
of ELISA methods.
The result of these efforts was accelerated licensure and avail-
ability of second-generation pneumococcal conjugate vaccines
[13,14].
2.4. Improved methods to do near real-time surveillance of health
care databases facilitates safety evaluation of vaccines
post-marketing
When vaccines are licensed, the clinical safety and efﬁcacy will
be based on a relatively small proportion of the population that
the licensed vaccine will target. Once a licensed vaccine goes into
widespread use, the inherent genetic diversity of the human pop-
ulation may result in AEs associated with vaccination that were
not possible to see during clinical trial evaluation. In order to
improve the post-market assessment of vaccine safety, the US FDA,
under the Sentinel Initiative, has launched the Post-licensure Rapid
Immunization Safety Monitoring (PRISM) program [15] and con-
ducts surveillance for inﬂuenza vaccine safety in the elderly using
data from Center for Medicare and Medicaid Services with novel
real-time surveillance methods [16] to build on the pioneering
efforts of the Centers for Disease Control and Prevention Vaccine
Safety Datalink [17]. Other international efforts, such as the Vaccine
Adverse Event Surveillance and Communication (VAESCO) project
in Europe, create the potential for a Global Vaccine Safety Datalink.
Use of near real-time surveillance not only allows for rapid identiﬁ-
cation of vaccine-related AEs, but also, in the absence of such events,
helps to improve public conﬁdence in the safety of the licensed
vaccine.
3. Gaps that could be addressed by a global regulatory
science agenda: Evaluating the quality of vaccines
Evaluation of vaccine quality to ensure safety and efﬁcacy poses
regulatory challenges for several reasons: (1) the complexity and
diversity of the products themselves due to their biological origin;
(2) the vulnerability to contamination of the biologic source materi-
als used to manufacture vaccines (e.g., eggs, mammalian cells, fetal
bovine serum, etc.); (3) many vaccines cannot withstand common
puriﬁcation and decontamination methods such as those used for
pure chemical compounds or less complex biologics (i.e., recombi-
nant proteins); and (4) evaluation of vaccine quality in many cases
relies on a bioassay with inherent issues regarding reproducibility
and robustness (e.g., animal challenge test, virus titration using cell
culture, etc.).
Together, these challenges could be addressed through the fol-
lowing approaches: (1) development of appropriate and improved
analytic methods and detection assays for infectious agents; (2)
understanding the critical attributes of the vaccine that generate
the protective immune response to enhance development of novel
quality-control methods for vaccines; and (3) robust manufactur-
ing processes as well as rigorous control of the source materials as
part of the evaluation to ensure product quality (i.e., application of
principles of Quality by Design) [18].
Some examples of advances that could be realized through a
coordinated regulatory science agenda follow.
3.1. Development of new potency assays for inactivated inﬂuenza
vaccines
Inﬂuenza virus changes both genetically and antigenically either
by a gradual process of antigenic drift, causing epidemics, or by
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udden and dramatic antigenic shift, causing pandemics. In
ractice, this means that updating the vaccine is considered annu-
lly, and new, clinically relevant strains regularly replace existing
accine strains when indicated by disease surveillance data. Efforts
o streamline the process for generating updated inﬂuenza vaccines
ould bring signiﬁcant public health beneﬁts. One area targeted for
mprovement is potency testing of inactivated inﬂuenza vaccines,
ither by developing new methods, as was the proof-of-principle
ase for the monovalent pandemic H1N1 vaccine in China described
bove, or by improving the existing method used to measure
nﬂuenza vaccine potency.
The current assay used for inactivated inﬂuenza vaccine is the
ingle radial diffusion (SRD) assay that measures biologically rele-
ant material, HA, in the vaccine and has been used successfully for
early forty years. It is an immunological assay requiring reagents
ncluding antigen and antibodies which must be matched to the
irus serotype used in the vaccine and thus requires updating
lmost every year; this is a time-consuming process.
Generation of reference antisera to HA typically involves enzy-
atic removal and puriﬁcation of the virus HA protein, which is
hen used to immunize sheep. The sheep sera containing these
train-speciﬁc antibodies are collected and used as a reference
tandard by manufacturers in potency tests for inﬂuenza vaccines.
hile this approach to developing anti-HA antibodies is usually
ffective, there have been instances where the particular char-
cteristics of some strains of inﬂuenza virus make it difﬁcult to
btain sufﬁcient amounts of HA. Therefore, an alternative approach
hat does not require the availability or puriﬁcation of inﬂuenza
irus to generate the HA immunogen has been developed. Using
ecombinant DNA techniques to derive plasmid DNA encoding for
A, the HA protein can be produced in vivo by direct injection
f the plasmid into sheep. The level of antibody production can
hen be boosted by subsequent injection into the sheep of a genet-
cally engineered viral vector encoding the same vaccine strain of
A. These sheep anti-HA antibodies have worked effectively in
otency assays designed to evaluate commercially produced H1N1
nd H5N1 vaccines, demonstrating the feasibility of an alternative
pproach to producing potency reagents [19].
In addition, availability of seasonal ﬂu vaccine may  be enhanced
y successful development, evaluation, and validation of alter-
ative potency assays. Any new assay would need to be an
mprovement upon current methods, measure antigenicity and
onitor vaccine stability, be practical, and ideally require smaller
or no) quantities of reference standards. Methods that are being
nvestigated include the use of reagents that cross-react with a
ange of different strains so they can be used in successive sea-
ons, methods that require smaller quantities of reagents so that
he production is less complex (e.g., it could abolish the current
eed for the industrial-scale production of antigen reagents) or the
se of physico-chemical methods adapted in some way  to measure
nly the biologically relevant conformation of the protein [20].
.2. Research on standardization for quality control and
mmunogenicity of a new enterovirus 71 vaccine
Since its emergence in the United States in 1969, enterovirus 71
EV71) has been recognized as a major public health issue across
he Asia-Paciﬁc region and beyond, causing hand-foot- and -mouth
isease (HFMD), with and without neurological and systemic com-
lications, and, in some outbreaks, high mortality. In 2008, the
umber of HFMD cases in mainland China amounted to 0.49 million
eported cases and 126 deaths; in 2009, 1.16 million cases and 353
eaths; in 2010, 1.77 million cases and 905 deaths; and in 2011,
.64 million cases and 506 deaths [21].
EV71 vaccines are being developed in China by more than
en manufacturers. Numerous challenges have slowed progress,S (2013) B163– B175
including selection of vaccine strains, comparison of immunogenic-
ity, and the lack of international and national standards as well as
validated models for quality control. To overcome some of these
challenges, the genetic and antigenic characteristics of different
candidate vaccine strains of EV71 were studied [22], preliminary
national reference standards for EV71 antigen and neutralizing
antibody were established, and suitable evaluation methods for
potency were devised by NIFDC [23]. In addition to these stud-
ies, the decline of maternal EV71 antibodies in infants has been
investigated, identifying that the ideal time point for primary
immunization for infants is around two  to ﬁve months of age
[24]. Consequently, today, EV71 vaccines from three manufacturers
have entered phase 3 clinical trials. However, remaining challenges
include developing suitable animal models so that the mechanisms
of pathogenesis and protection can be determined.
3.3. Novel vaccine production technologies
Vaccine production systems in general use are well established,
and include fermentation and the growth of viruses in cell cul-
ture. The use of recombinant DNA-based expression systems, such
as yeast, is well established, and the regulatory issues associated
with these systems have been considered in great depth over the
years, with a clear product development pathway [25]. There are
numerous other possible production systems, however, including
expression in insect cells [26] (or living insects), in transgenic ani-
mals and plants expressing foreign proteins, or in other novel cell
substrates, such as human tumor-derived cell lines. All these pose
their own speciﬁc regulatory issues to be dealt with, including
issues of potential tumorigenicity of residual components from the
production system, or unwanted contamination from adventitious
agents.
The beneﬁt-risk evaluation for vaccines requires especially care-
ful consideration. These are medicines usually given to healthy
individuals to protect against diseases that they may  never develop,
even without vaccination, and typically to very young children. The
acceptable level of risk and uncertainty is therefore very low, and
the regulatory approach used is extremely conservative. Therefore,
while novel production systems may  each provide speciﬁc beneﬁt
over traditional ones, they must be evaluated carefully, using the
best available science to establish an acceptable degree of conﬁ-
dence in the new technology.
Areas where regulatory science could impact use of novel vac-
cine production technologies include the following: (1) evaluating
the use of transgenic plants for development of oral vaccines and
whether such vaccines induce an inappropriate immune response;
(2) characterizing insect cell viruses for their zoonotic potential;
(3) evaluating whether a novel cell substrate would alter the anti-
genic phenotypes in a manner that impacts immunogenicity (either
positively or negatively), such as changes in glycosylation patterns
resulting from shifting from mammalian-based to insect-based, for
example; and (4) determining the quantity of residual host-cell
DNA that poses a risk and how to accurately measure the residual
DNA.
These examples show that continued regulatory research is
needed to develop new methods and understanding of the beneﬁts
and risks of new production substrates.
3.4. Development of new analytical methods
New analytical methods, especially if shown to be proxies of
vaccine efﬁcacy, may  strengthen in-process control and better eval-
uate the quality of the ﬁnished products. Mass spectrometry, NMR
spectroscopy, light scattering, and circular dichroism are useful
to study structural properties, product excipients, aggregates and
protein stability, and thus complement biological assays classically
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sed to characterize vaccines [27–29].  Additionally, they may  prove
seful to study vaccines derived from highly glycosylated glyco-
roteins, or based on bacterial capsule polysaccharides. However,
areful evaluation of new methods including validation against tra-
itional assays is required before they can be adopted for regulatory
urposes.
High-throughput sequencing (also known as “Massively Paral-
el” or “Next Generation” sequencing) has the potential to provide
ery high-resolution information about all the genetic sequences
resent in a preparation of a vaccine, manufacturing intermedi-
te, or raw materials used during manufacturing. Due to its higher
ensitivity and greater breadth for detection of contaminating
nfectious agents than conventional assays [30,31],  it has proven
o be very useful in identifying a previously unidentiﬁed infectious
gent (porcine circovirus) in a licensed rotavirus vaccine [32,33,34].
oreover, because the method provides sequence information on
 population of genomes within a preparation, rather than the most
ommon or consensus sequence, it can also be applied to evaluate
he genetic consistency of vaccines that contain nucleic acids from
iruses that are prone to mutate at high rates (i.e., RNA viruses)
35].
Reﬁnement or replacement of animal-based potency assays
o allow for more robust evaluation is another area of regula-
ory research. The application of an ELISA-based assay to measure
ouse antibodies to pertussis antigens in place of animal-based
hallenge assays is one such example [36]. In addition, in vitro toxin
eutralization or chemical and physiochemical assays may  provide
seful alternatives or additional tests to traditional methods to
easure potency [37,38].
. Gaps that could be addressed by a global regulatory
cience agenda: Non-clinical evaluation of vaccines
.1. Assays for novel adjuvanted vaccines
Subunit vaccines composed of recombinant or puriﬁed antigens
ave a good safety record but often are poorly immunogenic. The
se of immunostimulatory agents such as adjuvants can enhance
mmune response, but safety concerns arise due to the potential for
ver-production of inﬂammatory and pyrogenic molecules. Exist-
ng non-clinical studies of adjuvanted vaccines in animal models
ay  not always identify an increased risk for vaccine-associated
Es due to species-speciﬁc differences between the model and
uman population. Moreover, there is a gap in our understanding
f how some adjuvants exert their immune-potentiating activities
nd whether the adjuvant impacts the quality of vaccine-induced
rotective response. Improved understanding of the adjuvant mode
f action (MOA) will facilitate selection of the best adjuvant or deliv-
ry systems to achieve the desired immune responses for speciﬁc
athogens.
Another approach for additional toxicity screening tools is
uman cell-based assays that can predict in vivo effects of adju-
ants. For example, increased levels of proinﬂammatory cytokines
nd prostaglandin E2 (PGE2) were detected in monocytes exposed
o Toll-like receptor (TLR) agonists but not the approved adjuvants.
hen examined with an animal model, these same TLR agonists
nduced fever in New Zealand white rabbits that was preceded by
n early peak in plasma PGE2 levels [39].
Tools also have been developed to evaluate whether adjuvants
mpact the quality and breadth of antibody immune responses
gainst inﬂuenza vaccines, namely, whole genome phage display
ibraries (GFPDL) and surface plasmon resonance (SPR) [40]. These
ew tools allow measurement of the diversity, speciﬁcity, and
fﬁnity of vaccine-induced antibodies. It has been demonstrated
hat oil-in-water adjuvants (MF59, AS03) signiﬁcantly increasedS (2013) B163– B175 B167
the repertoire of antibody responses against pandemic inﬂuenza
(H5N1; H1N1pdm09) and helped to select for high-afﬁnity anti-
bodies targeting the hemagglutinin globular domain (HA1) [41,42].
The increased antibody afﬁnity correlated with improved neutral-
ization of both homologous and heterologous inﬂuenza strains.
Such cross-reactive antibodies are likely to provide better in vivo
protection against inﬂuenza strains with pandemic potential.
4.2. Identiﬁcation of correlates of immunity through non-clinical
evaluation
In some cases, measurement of neutralizing antibodies is insuf-
ﬁcient to evaluate the efﬁcacy of vaccines. In particular, with those
pathogens where a cell-mediated response may  be critical to vac-
cine efﬁcacy—such as HIV, TB, or malaria—it may be necessary to
perform non-clinical studies to identify markers that correlate with
protection in order to measure vaccine efﬁcacy in clinical trials.
As one example, the development of vaccines to induce T cell-
mediated immunity has been hindered by a limited understanding
of the complex cellular immune responses required to protect
against intracellular pathogens such as Mycobacterium tuberculo-
sis.  For example, speciﬁc vaccine-induced multifunctional T cell
responses that correlate with protection against tuberculosis in
animal models have been deﬁned using multi-parameter ﬂow
cytometry [43]. Additionally, novel in vitro culture assays have
identiﬁed cellular cytokine response proﬁles that are associated
with the inhibition of intracellular growth by M.  tuberculosis [44].
Exploring non-clinical methods and models such as those
described above is critical to ensure that the assessment of vaccine
efﬁcacy is accurate.
5. Gaps that could be addressed by a global regulatory
science agenda: Clinical evaluation of vaccines
5.1. Identiﬁcation of [additional] correlates of immunity
Historically, the protective efﬁcacy of vaccines was  established
through trials and epidemiological investigations which demon-
strated, for many vaccines, that protection from disease correlated
with levels of antibodies in the serum. For second-generation
vaccines targeting established antigens, clinical trials have been
simpliﬁed by measuring the speciﬁc antibody response to the vac-
cine. Using these immune correlates, it is also possible to assess the
overall community immune status by testing blood samples from
epidemiologically representative groups. Surveillance for antibod-
ies to tetanus, diphtheria, and Japanese encephalitis vaccines are
examples of this approach [45]. However, this is not possible for all
vaccine types as a direct correlation between antibody levels and
protective efﬁcacy has not been shown—tuberculosis, pertussis,
and HIV vaccines are examples. Moreover, the deﬁnition of “pro-
tective efﬁcacy” used in clinical studies, (e.g., whether protection
is against infection or disease, against laboratory-conﬁrmed cases,
viral load, or overt clinical disease), can also lead to different con-
clusions regarding efﬁcacy. Given the complex nature of endpoints
for clinical studies of different types of diseases and the vaccines
used to prevent them, multiple correlates may  be considered.
The complexity of evaluation of vaccine-induced immune
responses can also be illustrated by current inﬂuenza vaccines.
While the role of cell-mediated responses is postulated, no consen-
sus has been reached as to how assays should be standardized to
analyze these responses. In addition, vaccination against inﬂuenza
by different types of vaccine (inactivated versus live attenuated),
and/or a different route of administration may  be associated with
different protective mechanisms. Thus, a particular antibody titer
may  have relevance for protection for one vaccine but not others.
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or example, an HI antibody titer (≥1:40) that has proved to be
 protective level when induced by inactivated inﬂuenza vaccines
n primed individuals cannot be used as a correlate of protection
or intranasal live attenuated vaccines [46]. Furthermore, these
ifferent classes of vaccines appear to differ in their efﬁcacy in
liciting broadly neutralizing anti-inﬂuenza antibodies, relative to
he immune response following natural infection [47]. Regulatory
cience research projects that analyze the levels of broadly neutral-
zing antibodies as immune correlates could facilitate evaluation
f new vaccines, adjuvants, or even the nature of the virus strains
elected for use in seasonal inﬂuenza vaccines [47].
It is also recognized that for some diseases (tuberculosis, lep-
osy) there is a contribution from the natural immune response
o the infection to the disease pathology, and these responses
ay  complicate measurement of the speciﬁc protective immune
esponse [48]. For viral vaccines, in particular, it has been recog-
ized that there is a marked individual variation in the response
f the vaccinee [49], and investigation of biomarkers that could
redict immune response or toxicity would be of great value and
acilitate development of new vaccines.
For several diseases well-controlled by vaccines, there is no
ctive circulation of the disease-causing organism in the com-
unity as a result of successful vaccination, thus providing less
ffective “natural” boosting of immunity. Over time, a reservoir of
usceptible individuals may  build up in the community so that the
isease could be re-introduced should immunization services fail to
aintain a high level of coverage, as, for example, with measles or
iphtheria [50]. Established immune correlates of immunity enable
racking of the possible waning immunity in a population due to
ack of natural boosting and facilitates decisions about introduction
f further booster immunizations (e.g., the introduction of TdaP
accines [51]).
These examples illustrate the challenges in the development
nd testing of new vaccines against many diseases, as well as
n tracking waning immunity following immunization. Ongoing
esearch on correlates of protection from infection or disease is
ssential for regulatory authorities to evaluate the efﬁcacy of vac-
ines following clinical trials as well as on an ongoing basis [52–55].
While developers of new vaccines will propose assays and
arameters for evaluation of the clinical immunizing potency
f their products in clinical studies, regulatory authorities need
o investigate, evaluate, and collaborate to achieve international
greement on the relevance, accuracy, and sensitivity of these pro-
osals.
.2. Development of correlates of safety
Research on vaccines has constantly sought ways to further
ncrease the safety of these products. Regulators have responded
o such observations by implementing appropriate measures such
s those described below:
Abolishing the root cause for vaccine reactogenicity (e.g., by
lowering product-and process-speciﬁc impurities below levels
causing undue clinical effects).
Providing guidance for known risk populations (e.g., as regards
the use of live attenuated vaccines in immune-suppressed indi-
viduals).
Replacing starting materials (e.g. replacing mouse brain with tis-
sue culture for production of certain vaccines, such as JE and
rabies vaccines).
Enforcing stringent control speciﬁcations on critical starting
materials, such as cells or plasma derived from human or animal
origin to avoid transfer of infectious agents through vaccines.S (2013) B163– B175
These and other regulatory measures have been successful in
minimizing side effects caused by vaccination. Developing spe-
ciﬁc and sensitive assays predictive of allergic reactions which may
occur with the use of a given vaccine formulation or side effects in
subpopulations known to be particularly at risk (e.g., infants with
immature regulation of body temperature) will be very beneﬁcial.
Such assays are likely to be developed much faster compared to the
pharmacogenomic approach outlined further below.
Unlike markers or factors suggestive of common side effects,
no such tools are currently available for predicting rare and very
rare adverse effects following vaccination, most of which cannot
be detected even in very large clinical studies. Furthermore, very
severe clinical manifestations, such as severe allergic reactions,
new onset of autoimmune disorders, or even lethal outcomes such
as sudden unexpected death in infancy (SUDI) or sudden infant
death syndrome (SIDS) may  be coincidental to, or due to an error
in, administration of the vaccine, and not an inherent risk of the
vaccine. For some rare side effects, a probable link has been estab-
lished between vaccination and disease manifestation, such as
rotavirus vaccines and intussusception. It is very unlikely, how-
ever, that these rare adverse effects are triggered by vaccination
alone. Instead, vaccination may  be one of several factors which, if
combined, release a cascade of events ultimately resulting in an
unwanted outcome. The rarity of such events suggests that some
individuals may  have a genetic predisposition. Since any kind of
predisposition must be determined at a genomic level, identiﬁ-
cation and understanding of the signiﬁcance of single nucleotide
polymorphisms (SNP) or allele diversity of potential marker genes
would be desirable. Pharmacogenomics is a discipline of growing
importance within the ﬁeld of regulatory sciences. However, unlike
some chemically deﬁned medicinal products and one monoclonal
antibody (Pertuzumab “Herceptin”) for which speciﬁc genetic pre-
requisites are required for ensuring a positive beneﬁt/risk outcome,
no speciﬁc genetic signature has been identiﬁed for predicting an
increased risk of rare but severe side effects following vaccination
[56].
As pharmacovigilance systems are steadily reﬁned, the immu-
nization community should anticipate that increased numbers of
Suspected Unexpected Severe Adverse Reaction (SUSAR) will be
reported for new as well as for licensed vaccines. SUSARs may also
occur by chance in clinical studies. Frequently, studies are sus-
pended or stopped whenever SUSARs are observed. Matching rare
but very severe adverse reactions to individual allelic structures
would both facilitate diagnosis and also communications to the
public in situations where vaccines remain safe for the vast majority
of a target population. However, regulatory research on identifying
mechanisms of interaction between speciﬁc genetic backgrounds
and an immune response following vaccination will most likely
take years or even decades before usable results will become avail-
able.
5.3. Innovative clinical trial design
In recent years, innovative study designs have been proposed
to speed development of promising new vaccines, where an urgent
and unmet need exists. Diseases such as malaria, TB, and HIV are
especially challenging.
The goals of innovative trial designs are to (1) minimize the
number of ineffective candidate vaccines that proceed into Phase
2/Phase 3 trials; (2) enhance ability to identify promising candi-
date vaccines early; (3) more quickly obtain answers to scientiﬁc
questions of interest (e.g., establishing correlates of protection);
and (4) promote more efﬁcient use of resources. The sooner non-
promising vaccines can be eliminated, the more resources can be
diverted to development of vaccines that most likely will be effec-
tive. For example, innovative trial designs may allow greater rigor
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n Phase 2 studies and better inform the design of Phase 3 trials,
hus promoting more successful outcomes.
Various types of adaptive trial designs have been considered for
se with malaria, TB, and HIV vaccines [57], and stakeholders have
equested regulatory advice. Recognizing this need, regulatory con-
iderations on adaptive design trials have been published [58,59].
he US FDA views adaptive designs as those that prospectively plan
or changes in the design, optimally based on blinded evaluations of
ccumulating data within the clinical trial. Changes to trial design
ased on unplanned analyses and decision paths during interim
nalysis, and changes based on information completely external to
he trial, are not considered as adaptive designs.
Adaptive design trials demand very advanced biostatistical
kills at the level of the sponsor/Principle Investigator, Data Safety
onitoring Board, and regulatory authority in order to eliminate
oncerns about false positives and bias. Other innovations in study
esigns could also be considered (e.g., enrichment studies that may
arget speciﬁc subpopulations at elevated risk for disease or stud-
es that use biomarkers to deselect subjects for study if a vaccine is
ikely to cause an AE).
.4. Developing mathematical models for safety data
equirements across the product development lifecycle
A new regulatory approach to determine sample size in clinical
rials seeks to take advantage of improvements in post-marketing
afety studies to optimally allocate safety data collection at each
hase of the product development lifecycle. Clinical trials of vac-
ines are generally larger than those for other medical products
ecause of the very high standard of safety required for products
iven to very large numbers of healthy people, especially infants
nd children. Concern has been expressed that very large phase 3
rials, in the absence of a speciﬁc safety hypothesis, increase the
ime it takes to get innovative and lifesaving vaccines to people
ost in need [60]. While a variety of improvements have been pro-
osed [61], a theoretically optimal framework for deciding how
uch data are needed at each phase of the lifecycle is lacking. Sim-
lation of the vaccine development lifecycle has been proposed as
ne approach. For example, recent work linking infectious disease
ransmission and game theory models has allowed the system-
tic exploration of the interplay between disease risk and vaccine
afety and effectiveness in vaccination decision-making [62]. The
ndings of this initial effort indicate that for vaccine-disease situa-
ions where disease risk and vaccine efﬁcacy are sufﬁciently high,
ndividuals may  be more willing to tolerate greater uncertainty in
accine safety in the early years of an immunization program, espe-
ially in the case of diseases which have no current cure. In such a
ituation, shifting more safety data collection to the post-marketing
hase might be reasonable, assuming rigorous high quality studies
an be rapidly conducted. Additional research in both the structure
f the mathematical models and how to decide what constitutes
he acceptable vaccine risk is needed to advance this work.
. Gaps that could be addressed by a global regulatory
cience agenda: Post-marketing surveillance of vaccines
.1. Enhancing post-marketing surveillance of vaccine safety
A lifecycle approach to safety data collection depends on the
xistence of systems that can rapidly conduct rigorous post-
arketing vaccine safety studies to evaluate even rare AEsollowing immunization. However, spontaneous reporting sys-
ems, such as the US Vaccine Adverse Event Reporting System or
he Uppsala Monitoring Center’s Vigibase, which is part of WHO’s
rogramme for International Drug Monitoring and involves bothS (2013) B163– B175 B169
developed and developing countries, will also play an important
role in detecting serious unexpected AEs, especially in develop-
ing countries that might not have access to large population-based
electronic medical data.
Efﬁcient and rigorous analysis of spontaneous reports of AEs fol-
lowing immunization remains a challenge despite improvements
from the use of disproportionality data-mining methods [63].
Traditionally, spontaneous reports require evaluation by clinical
experts within a “case series” framework [64] to identify unusual
patterns requiring further investigation. The advent of dispropo-
tionality data-mining methods provides the ability to summarize
a large amount of information, but it is not a substitute for expert
review. Case-based reasoning is a sub-ﬁeld of artiﬁcial intelligence
in computer science that uses a variety of algorithmic [65] and
statistical [66] approaches to ﬁnd reports with “similar” charac-
teristics. Such approaches might facilitate expert identiﬁcation of
unexpected clinical patterns [67,68] or be used to classify reports
using text mining and natural language processing [69], with resul-
tant improvements in efﬁciency and timeliness.
The mining of social media for public health information has
received attention recently because of the success of “Google
ﬂu trends” (http://www.google.org/ﬂutrends/) and “HealthMaps”
(http://healthmap.org/en/) in identifying infectious disease out-
breaks, at least as quickly as traditional methods, but at lower
cost. It is a straightforward exercise to ﬁnd discussions of vac-
cine safety issues on internet blogs or larger services such as
Twitter using standard internet search tools. Most such postings
lack the necessary details that individual case safety reports sub-
mitted to spontaneous reporting systems collect, so case series
evaluations that are the mainstay of current spontaneous report
evaluation would likely be difﬁcult to conduct. However, if efﬁ-
cient approaches to aggregating the highest quality information
were developed, they might provide an earlier warning of emerging
safety concerns or be especially helpful for identifying geographi-
cally localized clusters for regulators and public health authorities.
Such approaches might be most effective in settings where no
reporting or weak spontaneous reporting systems are present.
Whether gathering such information would improve vaccine safety
surveillance remains to be investigated.
Setting up spontaneous reporting systems is resource intensive,
and in much of the developing world, email and internet connec-
tivity may  not allow for the mining of social media, so there might
be an opportunity to leapfrog these approaches because of the wide
penetration of mobile phones and other devices. Such an approach
would allow health professionals to inexpensively send an alert
to a central monitoring point regarding AEs. Such a project has
been tried in Nigeria for monitoring use of anti-malarial drugs [70].
The collation, investigation, and analysis of such reports remain a
challenge, but might be resolved by the development and deploy-
ment of artiﬁcial intelligence systems to conduct data mining and
semi-automated case-series evaluations that would provide cogent
summaries for human review. This would be simpler in the vaccine
context, where many countries have trained vaccinating staff and
a central EPI administration with an AEFI function.
7. Gaps that could be addressed by a global regulatory
science agenda: Cross-cutting research
7.1. Beneﬁt-risk methodologies
Regulatory opinions are based on balancing the desired effects
or ‘beneﬁts’ of a medicine against its undesired effects or ‘risks’.
Weighing up the beneﬁts and risks of a medicine is a complex pro-
cess, associated with some uncertainty, as the information that is
available at a given point in time may  be incomplete. To date, there
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s no standard methodology used to aid regulatory decisions on the
eneﬁts and risks of medicines and vaccines.
Regulatory research on beneﬁt-risk methodology aims to
evelop and test tools and processes for balancing multiple bene-
ts and risks, which can be used as an aid to inform, science-based
egulatory decisions about medicinal products.
A project on beneﬁt-risk methodology is under way in the EU
71]. The ﬁrst work package focuses on the current practice of
eneﬁt-risk assessment in the centralised procedure for medici-
al products in the EU regulatory network [72]. The second work
ackage examines the applicability of three frameworks and 18
uantitative approaches for assessing the beneﬁt-risk balance [73].
t was found that multi-criteria decision analysis (MCDA) [74],
n applied technology that arose from decision theory [75], can
rovide a theoretically sound basis for quantifying favorable and
nfavorable effects, including their clinical relevance and asso-
iated uncertainties, on a common scale that shows the balance
etween beneﬁts and risks. Following ﬁeld-testing of MCDA, it was
ecognised that a complete quantitative model might not always
e necessary [76]. Instead, two levels of methodology, depending
n the complexity of the beneﬁt-risk data to be assessed, may  be
sed.
The ﬁrst approach is qualitative, consisting of a table of effects
nd their uncertainties. This table allows simple visualisation of key
ffects to aid expert judgment of the beneﬁt-risk balance. For more
omplex situations (e.g., multiple conﬂicting effects), MCDA may
e a useful addition to aid the decision-making process. Also, the
rocess of monitoring the beneﬁt-risk balance of a medicinal prod-
ct post-approval could be supported in complex or marginal cases
f a quantitative model was available. As new data are received,
t would be possible to update the model with the new informa-
ion to see if the beneﬁt-risk balance has changed. The last work
ackage of the project is ongoing in the form of a pilot/training
hase focused on the new methodologies. A ﬁnal methodology
ill be agreed by the European Medicines Agency (EMA) based
n the received feedback. Once ﬁnalized, it would be of interest
o explore the applicability of the methodology in the context of
ther regulatory frameworks (outside the EU) in order to further
est the usefulness of reﬁned beneﬁt-risk approaches in different
ettings.
. Global regulatory science agenda: challenges
.1. Updating beneﬁt-risk analyses throughout the lifecycle of a
roduct: Scientiﬁc and regulatory management following
ost-licensing discovery of signals for possible viral adventitious
gents in live viral vaccines
The granting of a product license by a regulator can be consid-
red as starting the lifecycle of a licensed vaccine, which usually
asts for several decades. Within this time period, numerous
hanges to the manufacturing process are likely to be introduced
y manufacturers in order to apply state-of-the-art technology.
hese changes must be reviewed and approved by National Reg-
latory Authorities (NRAs). Likewise, increasing post-marketing
xperience will result in changes to product information pro-
ided to prescribers and patients. Depending on the number and
agnitude of approved changes introduced into a manufacturing
rocess or differences in safety and/or efﬁcacy proﬁles identiﬁed
y post-marketing surveillance systems compared to the pivotal
afety and efﬁcacy studies, the beneﬁt-risk ratios may  need to
e reconsidered and adapted. Moreover, due to the complexity
f vaccines and their respective manufacturing processes, out-of-
peciﬁcation batches may  occasionally occur which deviate from
icensed speciﬁcations and also need to be assessed individually.S (2013) B163– B175
Such assessments need to carefully balance any major supply issues
and their public health consequences caused by discarding affected
batches with the potential health risks associated with the use of
out-of-speciﬁcation batches. In many cases, appropriate risk analy-
ses of out-of-speciﬁcation data show they do not impact the original
beneﬁt-risk ratio. When risk analysis does suggest an impact on the
original beneﬁt-risk analysis, then an affected lot is removed from
the supply chain.
Recently, additional risks, undetected at the time of licen-
sure, have been identiﬁed for vaccines (and other biologicals).
In the 1990s, a laboratory found reverse transcriptase activity in
licensed measles vaccines. This followed use of a new assay based
on detection of reverse transcriptase activity with dramatically
increased sensitivity (the PERT assay). This enzyme is characteris-
tic of retroviruses but there are also cellular enzymes with reverse
transcriptase activity. A joint effort by industry and regulatory
agencies, coordinated through WHO, showed that the origin of the
reverse transcriptase activity was  an avian endogenous retrovirus,
which is an integral part of the genome of the chicken embryo
cells used to propagate the measles virus [77]. This endogenous
retroviral particle was shown to be non-infectious for humans and
posed no risk to vaccine recipients, so egg-based measles vaccines
remained on the market [78].
More recently, massively parallel sequencing detected genomic
DNA from porcine circoviruses in licensed live rotavirus vaccines
(see above). Further investigations revealed that contaminated
porcine trypsin used in the production process was  the source
of this contamination [33,34]. These laboratory data had to be
complemented by use of appropriate risk-assessment tools to
translate the scientiﬁc data into regulatory decisions, especially
as initial rapid decision-making is essential and information was
incomplete. Novel tools for assessing, quantifying, and inter-
preting risks associated with this type of contamination had to
balance the consequences of removing an affected vaccine from
the global markets, and its non-availability until the problem has
been resolved, with the risks associated with continued use of
the implicated product. Using such an approach, global agree-
ment was obtained to allow the products to remain on the market
[79].
8.2. Articulating the value of regulatory science in supporting
global access to safe and efﬁcacious vaccines
A global regulatory science agenda should support global access
to vaccines by addressing new products, new production tech-
nologies, new analytical methods, and by mediating an increased
understanding of the beneﬁts and risks of existing and future vac-
cines. In addition, regulatory science helps to meet the challenges
of academic and commercial vaccine development.
An example of a highly successful regulatory science project, in
the framework of an international collaboration which advanced
the development of a vaccine able to meet a signiﬁcant public
health need, is that of the MenAfriVac project. A new, safe, effec-
tive, and affordable conjugate meningitis vaccine, MenAfriVac was
developed from 2001 until licensure and WHO  prequaliﬁcation in
2009/2010. The vaccine was based on a new, more effective con-
jugation method developed by two regulatory researchers in the
Ofﬁce of Vaccines Research and Review in FDA’s Center for Biologics
Evaluation and Research (CBER). This chemical method improved
conjugation and simpliﬁed manufacture and puriﬁcation of the
vaccine’s active ingredient. Early in December 2010, a vaccination
campaign aimed at protecting millions of people in West Africa
was launched. By the end of December 2011, about 55 million peo-
ple whad been vaccinated with MenAfriVac during 2010 and 2011
[80].
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.3. Research on regulatory processes
Many regulators are restricted by law from allowing third-party
ccess to information or samples that they may  hold relating to
peciﬁc products. Access to raw data or to samples for academics
o design and test new approaches, or verify existing ones, may
herefore need agreements to be established with the manufactur-
rs who provided the information or samples in the ﬁrst place. In
he past, manufacturers have shared samples with regulators and
cademics, and the results of any research study, when published,
re usually blinded so as not to identify any one manufacturer’s
roduct. The use of samples submitted for lot release for research
urposes likewise needs to be agreed by manufacturers.
Concerns also relate to the release of conﬁdential data to
ational Immunization Technical Advisory Groups (NITAGs) for
he purpose of re-evaluating the beneﬁts/risks of vaccines. While
here may  be a need to expedite the path of new vaccines through
icensure to recommendations for use in national immunization
rograms, the roles and responsibilities of regulators and advi-
ory groups on immunization are different and need to be clearly
elineated. Nevertheless, ways of improving interaction between
he two parties, respecting clear roles and responsibilities and
ithin the bounds of conﬁdentiality, should be further explored.
or example, a more efﬁcient exchange of information between
he two types of organizations might beneﬁt the public at large
y facilitating, where appropriate, more timely access to vac-
ines.
.4. Limited pool of regulatory science expertise for vaccines
Regulation of biological medicines, including vaccines, is a spe-
ialized task. It requires evaluators skilled and experienced in the
anufacture and control of biologicals, the target diseases, ani-
al  modelling, and assessment of clinical evidence in the target
opulation—often infants. The developers and manufacturers of
accines are often the primary employers of persons with this
ange of expertise. Countries with established vaccine manufactur-
rs will generally have a greater pool of experts than other countries
here little, or no, expertise in vaccine manufacture or control may
xist.
Currently, vaccine-manufacturing facilities are based in a small
umber (n 40–45) of countries. These companies export and sup-
ly all other countries. Well-resourced regulatory authorities can
ecruit from a pool of experts without any major conﬂicts of inter-
st. A subset of these authorities has dedicated the resources to
aintaining a research effort required for regulatory science so that
nly a small number of effective regulatory science institutions for
accines (n < 10) exists throughout the world.
However, with appropriate coordination, the regulatory author-
ties in less-well-resourced countries, even with limited infrastruc-
ure, can contribute to global regulatory science activities in a
umber of ways. These include speciﬁc joint collaborative research
rojects; surveillance data reports; or collection of clinical or prod-
ct samples that may  facilitate research by established institutions.
hese activities should be linked into existing training programs
nd other capacity-building activities in participating countries,
uch as the Global Vaccine Safety Initiative [81].
. Proposed cross-cutting strategies and actions to support
 global regulatory science agendaSpeciﬁc gaps that can be addressed by a global regulatory sci-
nce agenda have been described in detail in preceding sections.
n addition, a number of cross-cutting strategies and actions are
dentiﬁed below.S (2013) B163– B175 B171
9.1. Sample repositories
Prior to adoption in regulatory settings, new assays and ref-
erence preparations developed in research laboratories must be
validated for regulatory use, ideally using a diverse range of vaccine
samples as differences in formulation and manufacturing processes
can markedly affect test results. Access to a range of vaccine lots that
have passed or failed existing tests is also critical for evaluating new
testing methods. For example, OPV lots that had passed or failed
the monkey neurovirulence test were essential during the devel-
opment and international collaborative evaluation of the MAPREC
and transgenic mouse tests (see above). Moreover, discrepancy in
testing results between regulators can be resolved through shar-
ing of samples, assays, and/or standards. Such samples are useful
to evaluate new methods, particularly if they are on the borderline
between ‘pass’ and ‘fail’ in existing tests. The establishment of one
or more international sample repositories is therefore one cross-
cutting strategy to support a global regulatory science agenda. AIDS
Reagents repositories such as the NIH AIDS Research and Reference
Reagent Program and NIBSC Centre for AIDS Reagents illustrate how
this might be done. It could be envisaged that WHO  Collaborating
Centres would act to facilitate sample storage and exchanges in the
wider international community.
9.2. International, regional, and national reference preparations
Biological products, including vaccines, are quantitated in terms
of the biological activity they contain. For a vaccine, this is the
amount of immunogen, deﬁned as the amount of material required
to generate an acceptable immune response in recipients. For many
vaccines, the immune response generated in animal models is used
to quantitate immunogenicity. Currently, in vitro methods (e.g.,
ELISA) which measure antigen—rather than immunogen—content
are of interest as alternates. As the assays involve biological activity
measured in a biological assay, and measurement of physical mass
does not necessarily correlate with outcome, it is often scientiﬁ-
cally inappropriate to express results from such assays in grams
or SI units. Similar considerations apply to the measurement of
antibody responses in clinical trials or serum surveys.
It is important to be able to compare results between studies,
between sites, and over time. Comparison is made possible by the
inclusion of a reference material in the relevant assays, and express-
ing the results obtained with the unknown relative to results with
the reference. This principle has been applied since the early days
of biologicals and has proved extremely powerful. International
reference materials are established by WHO. The process involves
preparation of the material in a stable form, usually lyophilised in a
large number of ampoules containing the same amount of material
to within tight limits. This material is then assayed by a number
of interested and competent laboratories using assays they con-
sider suitable. Other materials are assayed at the same time and
the results analyzed to establish whether expression of results rel-
ative to the reference material reduces the variation between and
within laboratories. The extent to which variation is reduced by
expressing the results in terms of the common candidate reference
material can be very striking.
While WHO  reference materials are made in batches of several
thousands, the supply is clearly limited, so the purpose of the WHO
primary standard is to calibrate secondary regional or national ref-
erence materials for use in routine assays. In some countries, the
National Control Laboratory prepares standards calibrated against
the primary standard. However, preparation of national standards
is costly and expertise to do so is limited in many countries. Prepa-
ration of regional secondary reference materials is preferred. The
regional activities of the European Directorate for the Quality of
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edicines (EDQM) and the South East Asian Regional Ofﬁce of WHO
re excellent examples.
.3. Active safety surveillance in selected low- and
iddle-income countries when new vaccines are introduced
Many countries have limited capacity and experience in imple-
enting epidemiological vaccine safety studies. In the past, the
vailability of comprehensive vaccine safety assessment systems
n the US and EU has also served the global need to evaluate
ew vaccines because most new vaccines were manufactured and
ntroduced in the US and Europe prior to use elsewhere. How-
ver, new vaccines (e.g., meningitis A, malaria) are now being
ntroduced or soon will be introduced either exclusively in the
eveloping world or concurrently with their release in Europe and
he US. Also, many vaccines that are procured globally are man-
factured outside of the EU or US. Therefore, developing global
nd regional capacity to evaluate vaccine safety is highly desirable
oth to assure the safety of the world’s vaccine supply, and also to
revent perceived vaccine safety concerns from undermining suc-
essful vaccination programs. Serious medical events of unknown
rigin, which can occur in temporal association with vaccination,
an be mistakenly attributed to vaccines, thus derailing vaccination
rograms that would otherwise be very beneﬁcial for the popula-
ion [82].
Unfortunately, most low- and middle-income countries do not
ave the resources or technical capacity to implement timely and
ccurate traditional epidemiological studies of vaccine safety. Lack
f training and absence of accurate population denominators are
mong the contributing reasons. In addition, most countries do not
ave the population size needed for the evaluation of very rare
Es. This highlights the need for taking a collaborative interna-
ional approach, led by WHO, to the epidemiological investigation
f serious and rare vaccine safety concerns.
To demonstrate that it is feasible to establish a collabo-
ative, WHO-supported consortium of vaccine safety researchers
nd their respective organizations from developed and middle-
ncome countries, a proof-of-concept study that investigated
he risk of Guillain-Barré Syndrome (GBS) following H1N1 pan-
emic inﬂuenza vaccination was initiated. Medical hospitalization
atabases or registries were utilized to assess the risk of a medi-
al outcome (GBS) following vaccination. Before choosing a study
ethodology, the consortium ﬁrst analyzed what the basic require-
ents would be for a collaborative approach of this kind (intended
o be inclusive of low- and middle-income countries). It was
oncluded that the ideal methodology would need to be sim-
le so it could be implemented easily, and standardized for all
ites. It was also decided that the investigation needed to be
imely and use only resources already available in the local pub-
ic health system, and avoid the need for population denominators
as they are either unavailable or grossly inaccurate in most low-
nd middle-income countries). Therefore, a cohort study design,
hich usually requires signiﬁcant organization and resources in
ddition to accurate denominator population, would not have
een suitable. Although a case control study design could be
ffordable, bias would be a signiﬁcant problem (and difﬁcult
o resolve).
The consortium, therefore, chose for this proof-of-concept
tudy a self-controlled case series (SCCS) methodology because
f its ﬂexibility and applicability to countries where popula-
ion denominator information may  not be available. The SCCS
ethod [83,84] has been shown to be valid and efﬁcient com-
ared to alternative approaches (e.g., cohort and case-control
esigns) [85–87].  In an SCCS study, the individuals are essen-
ially matched to themselves. Because of this implicit control of
ithin-person characteristics, this design efﬁciently controls forS (2013) B163– B175
all potentially non-time-dependent confounding characteristics,
including demographics, co-morbid conditions, genetic suscepti-
bility, and other characteristics that might not be measurable. As
this collaborative approach would primarily be needed for seri-
ous (and mostly rare) AEs, it was  determined that hospitalized
cases should be adequate. Moreover, the requirement for an SCCS
design is not to identify all cases of a disease, but to obtain an
unbiased set of cases. For this purpose, the identiﬁcation of all
hospitalized cases of a serious disease or event during a period
pre-speciﬁed by the research team would be appropriate. To allow
data from the different sites to be comparable, a common study
process and a standardized Brighton Collaboration case deﬁnition
were used by all sites. The success of this initial proof-of-concept
study is currently being analyzed. This study and approach can be
expanded further in the future to include low-income countries, as
well.
9.4. Coordination of regulatory science efforts
The international nature of vaccine supply and demand,
plus increasingly complex vaccine supply chains, coupled with
limited resources, strongly argue for international coordination
of regulatory science efforts. Accordingly, a number of bi- or
multi-lateral agreements between like-minded countries are being
developed. In addition, and due to the global nature of access
to vaccines, a globally coordinated effort is required. There is
a strong history of WHO-led workshops and consultations in
this area—for example, the series of workshops on pandemic
inﬂuenza spearheaded by WHO/US FDA/HC in 2006, three years
prior to the H1N1 outbreak in 2009. These proactive efforts
enabled regulatory agencies to be better-positioned to identify
the regulatory gaps, formulate strategies, and provide meaningful
guidelines. Very importantly, the WHO  umbrella enables devel-
oping countries to participate, for example, in the development
and validation of international reference standards and lot release
assays.
Another dimension is the interdisciplinary nature of the
required coordination. In particular, linking the regulatory com-
munity with the academic research community around diseases,
vaccines, and immunology would provide additional innovation
and input. The examples of developing correlates of protection for
pneumococcal conjugate vaccines [12] clearly indicate the regula-
tory beneﬁts to be gained from high-quality academic research on
target diseases and immunology.
9.5. Global regulatory science exchange and capacity-building
Scientists who  fully understand how to apply science to address
regulatory needs primarily work with or are closely afﬁliated
with NRAs, and several NRAs employ research-reviewer scientists.
Opportunities for regulatory science exchange between scientists
in countries without regulatory science programs and those with
advanced regulatory science programs will provide an important
means toward regulatory science capacity-building.
As an example, the US FDA has a relatively new regulatory
science capacity-building program developed initially within
the National Center for Toxicological Research (NCTR). This
International Scientist Exchange Program, or ISEP, provides an
opportunity for scientists from countries with less-developed
or no regulatory science programs to receive training in FDA
laboratories for a period of three to six months. By actively
working in a regulatory science research environment, the scien-
tists learn and practice the core principles of regulatory science
necessary to support the development of regulatory systems in
their home country. While this program is still relatively new, it
provides one example of an approach that could be broadened
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o incorporate a network of ongoing regulatory science programs
hat are more advanced, whereby interested scientists from
eveloping countries could choose the laboratory of interest
ased on the availability of resources and identiﬁed need. The
otential beneﬁt of this type of program is to inculcate more than
ust scientiﬁc training, per se, but also the philosophy of how to
pply science to address regulatory needs, thus promoting an
ncreased scientiﬁc base for advancing science-based policy and
ecision-making.
0. Conclusions
Inputs and ideas have been obtained from a broad range of reg-
lators and synthesized into a proposed global regulatory science
genda for vaccines. Regulators have responded with great inter-
st and have enthusiastically engaged in this initiative. Numerous
istorical and recent examples demonstrate the value and impact
f applied regulatory science research on vaccine safety, efﬁcacy,
uality, and performance. Regulatory science research is clearly
ritical to developing relevant, robust methods to evaluate vaccine
uality.
Current needs in regulatory science research include research to
mprove methods to measure vaccine potency to avoid or reduce
se of animals or to increase the predictive value of the assay;
dentify appropriate methods to assess novel vaccine production
ethods; and develop and validate new high-resolution analytic
ethods for assessing vaccine quality and safety, such as NMR,
ass spectrometry, and high-throughput sequencing. New tools
hould be developed to better evaluate the quality and breadth of
mmune responses and predict toxicity of adjuvants. Non-clinical
ethods should be developed to better evaluate cell-mediated
mmune responses to identify immune correlates of protection fol-
owing the use of vaccines. Given the complex nature of endpoints
or clinical studies of different type of diseases and the vaccines
sed to prevent them, multiple immune correlates should be con-
idered. The development of highly predictive correlates of safety
hould have high priority on a regulatory research agenda. The
evelopment of innovative approaches to clinical trial design so
s to speed up the evaluation of promising new vaccines, mini-
ize the number of ineffective candidates that proceed to phase
 studies, and promote efﬁcient use of resources is also highly
esirable.
Regulatory science should also explore new approaches to vac-
ine clinical trial design by taking advantage of improvements in
ost-marketing safety studies. Enhancing post-market surveillance
f vaccine safety by using novel real-time surveillance methods
s well as mining of social media is also envisaged. It would
lso be beneﬁcial to develop standard beneﬁt-risk methodol-
gy to aid regulatory decisions on vaccines, including reﬁning
isk-beneﬁt analysis for use throughout a licensed vaccine’s
ifecycle.
Additional linkages are needed with science and technology
ommunities to nurture the proposed innovations in vaccine reg-
lation. An agreed Global Regulatory Science Agenda will enable
ynergies to be established where none currently exist. Further,
uch an agenda will facilitate the spread of regulatory expertise
nd the beneﬁts of regulatory science to the less-well-resourced
ountries. Indicators to monitor and evaluate the progress of
uch activities could be targeted but not be limited to narrow-
ng the gaps in regulatory sciences between the developed and
eveloping countries and increased convergence of regulations
n vaccines. This concept paper can be used to develop a plan
f action to implement the ﬁrst ever global regulatory science
genda.
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